In 2018, a forty-two-year-old woman walked into an emergency department in suburban Virginia with crushing chest pain, shortness of breath, and radiating discomfort in her jaw and left arm. She was triaged, given an EKG — which showed normal sinus rhythm — and waited three hours before being evaluated by a physician, who ordered a chest X-ray and basic labs and diagnosed her with anxiety. She was discharged with a prescription for lorazepam and a referral to a therapist.
Two days later, she collapsed at home and was rushed back to the same emergency department. This time, cardiac biomarkers revealed a significant myocardial infarction — a heart attack. Emergency catheterization showed an 85% occlusion of her left anterior descending artery. She survived. But the delay in diagnosis — rooted in the assumption that a forty-two-year-old woman with chest pain was anxious rather than having a cardiac event — had allowed substantial myocardial damage that would affect her heart function for the rest of her life.
This is not an isolated case. It is a pattern so consistent that it has been quantified and published in peer-reviewed journals dozens of times. And it represents one visible manifestation of a far deeper problem: a healthcare system that was designed around male physiology, tested primarily on male subjects, and remains imperfectly equipped to diagnose and treat the health conditions of half the human population.
The clinical trial exclusion
The most consequential decision in the history of women's health was bureaucratic, well-intentioned, and catastrophically wrong. In 1977, the FDA issued guidelines recommending the exclusion of women of "childbearing potential" from Phase I and early Phase II clinical trials (FDA, 1977). The rationale was protective: thalidomide had caused devastating birth defects in the 1960s, and regulators wanted to protect potential fetuses from experimental drug exposure.
The consequence was a decades-long systematic exclusion of female subjects from the foundational research that determined how drugs were developed, dosed, metabolized, and prescribed. When women were later included in Phase III trials, they were typically included in numbers insufficient to detect sex-specific differences in drug response. Dosing was established in male bodies. Side effect profiles were characterized in male bodies. The entire pharmacopoeia was, to a striking degree, built on male data.
This exclusion was not reversed until 1993, when the NIH Revitalization Act mandated the inclusion of women and minorities in NIH-funded clinical research. But mandating inclusion and achieving adequate representation are different things. An analysis published in the Journal of Women's Health found that as recently as 2020, women constituted only 41% of participants in cardiovascular clinical trials — despite cardiovascular disease being the leading cause of death for women (Jin et al., 2020). In drug trials submitted to the FDA between 2000 and 2020, only 10% of studies reported sex-stratified efficacy analyses (Feldman et al., 2019).
The practical consequences of this research gap are extensive and documented. The sleep medication zolpidem (Ambien) was prescribed at the same dose for men and women for over two decades before the FDA discovered in 2013 that women metabolize the drug more slowly, leading to dangerously elevated morning blood levels that impaired driving ability. The FDA cut the recommended dose for women in half — twenty years after the drug hit the market (Greenblatt et al., 2014). How many vehicle accidents occurred during those twenty years because of a dosing error rooted in inadequate sex-specific research?
The pain gap
No domain illustrates the women's health gap more clearly than pain management. A systematic body of research has documented that women's pain is taken less seriously, evaluated less urgently, and treated less aggressively than men's pain across virtually every clinical setting.
A study published in Academic Emergency Medicine used standardized patient vignettes — identical clinical presentations with the patient's sex as the only variable — and found that emergency physicians were significantly less likely to administer opioid analgesia to female patients with acute abdominal pain compared to male patients with identical presentations, and significantly more likely to recommend sedative or anti-anxiety medication instead (Chen et al., 2008). The women waited longer, received less pain medication, and were more likely to be diagnosed with a psychological rather than somatic condition.
This is not a single study. A meta-analysis of 77 studies published in the Journal of Pain found that women consistently received less aggressive pain treatment than men across multiple clinical contexts, including post-surgical care, emergency departments, and chronic pain clinics (Hoffmann & Tarzian, 2001). The effect was compounded by race: Black women experienced the most significant treatment disparities, receiving the least aggressive pain management of any demographic group studied.
The mechanisms underlying the pain gap are both biological and cultural. On the biological side, nociceptive processing (pain signaling) differs between sexes: women have higher density of pain receptors in some tissues, and hormonal fluctuations across the menstrual cycle affect pain sensitivity and analgesic response. Sex differences in opioid receptor distribution mean that some analgesics are more effective in men while others are more effective in women (Craft, 2003). Research on these differences has been historically neglected.
On the cultural side, the pain gap reflects deeply embedded assumptions about women's relationship to physical distress. The historical concept of "hysteria" — a diagnosis applied exclusively to women for centuries, attributed to a wandering uterus, and treated variously with institutionalization, hysterectomy, and clitoral manipulation — cast women's physical complaints as inherently psychological in origin. While no modern physician would diagnose "hysteria," the underlying assumption — that women's reported symptoms may reflect emotional rather than physical pathology — persists in clinical practice in measurable ways (Tasca et al., 2012).
The diagnostic delay
The pain gap extends to diagnostic timelines. Women with autoimmune diseases — conditions that disproportionately affect women (approximately 80% of autoimmune disease patients are female) — experience an average diagnostic delay of 4.6 years, compared to 2.1 years for men with the same conditions (Autoimmune Association, 2021). For endometriosis, which affects approximately 10% of reproductive-age women and causes debilitating pain, the average diagnostic delay is 7-10 years from symptom onset (Greene et al., 2009).
These delays are not benign. They represent years of unmanaged symptoms, progressive disease, unnecessary suffering, and often irreversible damage. A woman with undiagnosed celiac disease loses bone density for years before treatment. A woman with undiagnosed lupus develops organ damage that earlier intervention might have prevented. A woman with undiagnosed endometriosis undergoes years of unnecessary interventions and experiences declining fertility.
The cardiovascular blind spot
Heart disease is the leading cause of death for American women, killing more women annually than all cancers combined. Yet the cardiovascular research enterprise, the clinical training infrastructure, and the public awareness campaigns have historically centered male cardiovascular disease — creating a blind spot that persists despite decades of advocacy.
The fundamental problem is that cardiovascular disease presents differently in women. The "Hollywood heart attack" — sudden crushing chest pain with radiation to the left arm — is the classic male presentation. Women are more likely to experience atypical symptoms: jaw pain, nausea, fatigue, shortness of breath, back pain, and an overall sense of something being wrong that may not include classic chest pain at all (McSweeney et al., 2003). These atypical presentations are less well-recognized by clinicians, less responsive to standard diagnostic algorithms, and more likely to be attributed to non-cardiac causes.
The consequences of this diagnostic mismatch are measurable and severe. A study published in Circulation found that women presenting to emergency departments with heart attacks were 50% more likely than men to receive an initial misdiagnosis — and that diagnostic delay was associated with significantly higher mortality (Pope et al., 2000). Women were more likely to be sent home from the emergency department during an active heart attack than men with identical biomarker profiles.
The underlying coronary artery disease pathology also differs by sex. Women are more likely to develop microvascular coronary disease — disease of the small blood vessels rather than the large epicardial arteries — which is not detectable on standard coronary angiography. This means that a woman can have a normal angiogram and still have significant coronary disease. The condition, previously dismissed as "syndrome X" or "non-cardiac chest pain," is now recognized as ischemia with non-obstructive coronary arteries (INOCA) and affects an estimated 3-4 million American women (Bairey Merz et al., 2017).
Reproductive health as "niche"
One of the most revealing aspects of the women's health gap is the medical system's treatment of reproductive health conditions as specialty concerns rather than primary health issues. Conditions that affect millions of women — endometriosis, polycystic ovary syndrome (PCOS), fibroids, severe menstrual disorders — receive research funding and clinical attention disproportionately small relative to their prevalence and impact.
NIH funding for endometriosis research was approximately $18 million in 2022 — for a condition affecting an estimated 6.5 million American women with economic costs exceeding $80 billion annually (NIH, 2023; Soliman et al., 2018). For comparison, NIH spent approximately $280 million on sleep research for a condition with a similar prevalence. The implicit message is that conditions unique to women's reproductive health are less important, less complex, or less deserving of scientific attention than conditions shared by both sexes.
Menopause represents another profound gap. The menopausal transition — which every woman who lives past approximately 50 will experience — involves dramatic hormonal changes that affect cardiovascular function, bone density, cognitive function, metabolic health, mood, sleep, and quality of life. Yet hormone replacement therapy (HRT), the most effective treatment for menopausal symptoms, has been mired in controversy since the Women's Health Initiative (WHI) study reported increased breast cancer and cardiovascular risk in 2002 (Writing Group for the WHI Investigators, 2002).
Subsequent reanalysis of the WHI data has substantially revised those conclusions: for women initiating HRT within 10 years of menopause onset, the risk-benefit profile is favorable, with cardiovascular protection, bone density preservation, and significant symptom relief outweighing the modest increase in breast cancer risk (Manson et al., 2013). But the initial panic led to an 80% decline in HRT prescriptions, and many physicians — particularly those trained during the WHI era — remain reluctant to prescribe it. An estimated 80% of menopausal women with bothersome symptoms do not receive treatment (Sarrel et al., 2015).
What closing the gap requires
The women's health gap will not be closed by good intentions, awareness campaigns, or incremental improvements to a system designed around male physiology. It requires structural change across multiple domains:
Research equity. Clinical trials must not only include women in adequate numbers but must also be powered to detect sex-specific differences in drug efficacy, dosing, metabolism, and side effects. Sex-stratified analysis should be mandatory for all trials submitted to the FDA.
Education reform. Medical school curricula must integrate sex and gender differences throughout the entire curriculum rather than confining women's health to the obstetrics and gynecology rotation. A survey found that only 10% of medical schools had a formally integrated sex and gender medicine curriculum (Jenkins et al., 2016).
Clinical recognition. Diagnostic algorithms for common conditions — particularly cardiovascular disease, autoimmune disease, and pain conditions — must be updated to reflect sex-specific presentation patterns.
Research funding. Conditions unique to or disproportionately affecting women — endometriosis, PCOS, fibroids, menopause, pregnancy-related complications — require research funding proportional to their prevalence and burden. The current allocation reflects historical biases, not scientific or public health priorities.
Patient empowerment. Until the system changes — which will take years — women must be informed advocates for their own care. This means understanding that sex-specific differences in disease presentation exist, that diagnostic delay is a documented risk, and that advocacy — asking questions, requesting specific tests, seeking second opinions, and insisting on being heard — is not difficult behavior but necessary self-protection in a system that was not built for you.
The story of the woman in the Virginia emergency department is not a story about one bad doctor. It is a story about a medical system that, for decades, built its knowledge base by studying men, defaulted to male norms when interpreting symptoms, and systematically undervalued the clinical experiences of women. Changing that system is not only a matter of scientific rigor and clinical quality. It is a matter of justice.
References
- Autoimmune Association. (2021). Autoimmune Disease Diagnostic Delay. Autoimmune Association.
- Bairey Merz, C. N., et al. (2017). Ischemia and no obstructive coronary artery disease (INOCA). Circulation, 135(13), e1148–e1157.
- Chen, E. H., et al. (2008). Gender disparity in analgesic treatment of emergency department patients with acute abdominal pain. Academic Emergency Medicine, 15(5), 414–418.
- Craft, R. M. (2003). Sex differences in opioid analgesia: From mouse to man. Clinical Journal of Pain, 19(3), 175–186.
- FDA. (1977). General Considerations for the Clinical Evaluation of Drugs. Food and Drug Administration.
- Feldman, S., et al. (2019). Quantifying sex bias in clinical studies. PLOS ONE, 14(7), e0218714.
- Greenblatt, D. J., et al. (2014). Zolpidem and gender: Are women really at risk? Journal of Clinical Psychopharmacology, 34(1), 1–5.
- Greene, R., et al. (2009). Diagnostic experience among 4,334 women with surgically confirmed endometriosis. Fertility and Sterility, 91(1), 32–39.
- Hoffmann, D. E., & Tarzian, A. J. (2001). The girl who cried pain: A bias against women in the treatment of pain. Journal of Law, Medicine & Ethics, 29(1), 13–27.
- Jenkins, M. R., et al. (2016). Sex and gender in medical education. Biology of Sex Differences, 7(1), 45.
- Jin, X., et al. (2020). Women's participation in cardiovascular clinical trials. Circulation, 141(7), 540–548.
- Manson, J. E., et al. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the WHI. JAMA, 310(13), 1353–1368.
- McSweeney, J. C., et al. (2003). Women's early warning symptoms of acute myocardial infarction. Circulation, 108(21), 2619–2623.
- NIH. (2023). Estimates of Funding for Various Research, Condition, and Disease Categories. National Institutes of Health.
- Pope, J. H., et al. (2000). Missed diagnoses of acute cardiac ischemia in the emergency department. NEJM, 342(16), 1163–1170.
- Sarrel, P. M., et al. (2015). Incremental direct and indirect costs of untreated vasomotor symptoms. Menopause, 22(3), 260–266.
- Soliman, A. M., et al. (2018). The burden of endometriosis symptoms on health-related quality of life. Journal of Comparative Effectiveness Research, 7(5), 439–452.
- Tasca, C., et al. (2012). Women and hysteria in the history of mental health. Clinical Practice and Epidemiology in Mental Health, 8, 110–119.
- Writing Group for the WHI Investigators. (2002). Risks and benefits of estrogen plus progestin. JAMA, 288(3), 321–333.